Turner Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Turner Syndrome Clinical Trials Overview
The Turner Syndrome clinical trial report consists of 86 trials. The report provides an overview of the Turner Syndrome clinical trials scenario. The report provides top-line data relating to the clinical trials on Turner Syndrome. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report includes the names of prominent sponsors involved with conducting the Turner Syndrome clinical trials as well.
Key Regions | · Asia-Pacific
· Europe · North America · Middle East and Africa · South and Central America |
Key Countries | · The US
· France · Netherlands · South Korea · The UK · China · Denmark · Germany · Spain · Russia |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · Novo Holdings AS
· Eli Lilly and Co · E. Merck KG · Ferring Holding SA · Pfizer Inc · LG Corp · Others |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Turner Syndrome Clinical Trials Segmentation by Regions and Countries
Europe led the Turner Syndrome clinical trials landscape with more than 40% of the clinical trials conducted there as of September 2023.
The key regions considered for Turner Syndrome clinical trials analysis are Asia-Pacific, Europe, North America, Middle East and Africa, and South and Central America.
In a country-wise analysis, as of September 2023, the US accounted for the highest number of Turner Syndrome clinical trials, followed by France and the Netherlands.
G7 countries: Among the G7 (United States, United Kingdom, Germany, Canada, Japan, France, and Italy) countries, France has the highest proportion of Turner Syndrome to Genetic Disorders clinical trials as of September 2023.
E7 countries: Among the E7 (China, India, Russia, Turkey, Brazil, Mexico, and Indonesia) countries, Russia has the highest proportion of Turner Syndrome to Genetic Disorders clinical trials as of September 2023.
Turner Syndrome Clinical Trials Analysis by Regions, 2023 (%)
Buy Full Report for More Regional Insights into the Turner Syndrome Clinical Trials
Turner Syndrome Clinical Trials Segmentation by Sponsor Types
The key sponsor types for Turner Syndrome clinical trials are company, institution, and the government. As of September 2023, the company sponsor type dominated the Turner Syndrome clinical trials share, followed by institution.
Turner Syndrome Clinical Trials Analysis by Sponsor Type, 2023 (%)
Buy Full Report for More Sponsor Type Insights into Turner Syndrome Clinical Trials
Turner Syndrome Clinical Trials - Competitive Landscape
In 2023, Novo Holdings AS conducted the highest number of Turner Syndrome clinical trials.
Some of the leading sponsors for Turner Syndrome clinical trials are:
- Novo Holdings AS
- Eli Lilly and Co
- Merck KG
- Ferring Holding SA
- Pfizer Inc
- LG Corp
Turner Syndrome Clinical Trials Analysis by Sponsors, 2023 (%)
Buy Full Report to Know More About the Leading Players of Turner Syndrome Clinical Trials Download a Free Sample Report
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies concerning investment.
- Helps identify prominent locations for conducting clinical trials, saving time and cost.
- Provides top-level analysis of the global clinical trials market which helps identify key business opportunities.
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Eli Lilly and Co
E. Merck KG
Ferring Holding SA
Pfizer Inc
LG Corp
Changchun High-Tech Industry Group Co Ltd
Dong-A Socio Group
Arya Tina Gene Company
Ascendis Pharma AS
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of Turner Syndrome clinical trials?
Europe accounted for the highest number of Turner Syndrome clinical trials as of September 2023.
-
Which country conducted the highest number of Turner Syndrome clinical trials?
The US conducted the highest number of Turner Syndrome clinical trials as of September 2023.
-
Which sponsor type was the most prominent in the Turner Syndrome clinical trials?
Company was the most prominent sponsor type for Turner Syndrome clinical trials.
-
Who are the leading sponsors of Turner Syndrome clinical trials?
Some of the leading sponsors of Turner Syndrome clinical trials are Novo Holdings AS, Eli Lilly and Co, E. Merck KG, Ferring Holding SA, Pfizer Inc, and LG Corp, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.